Kubo Hidefumi, Nishiyama Mitsuo, Tada Kosuke, Miyahara Makoto, Hasegawa Hiroyasu
Dept. of Surgery, Tokuyama Central Hospital, Japan.
Gan To Kagaku Ryoho. 2013 Jan;40(1):99-102.
A 35-year-old woman underwent hemicolectomy and RFA for ascending colon cancer with multiple liver metastases in February, 2005. She received postoperative hepaticarterial infusion chemotherapy with 5-FU, and systemic hemotherapy with UFT for 10 months after the operation. A local recurrence of the anastomosis was detected in March, 2006, and she underwent a resection for it. This was followed by 6 courses of adjuvant chemotherapy with modified FOLFOX6. Because multiple liver metastases and lymph node metastases were detected in March, 2007, she received RFA and 6 courses of adjuvant chemotherapy with modified FOLFOX6 again. Liver metastases disappeared but lymph node metastases still remained. Therefore, she received 4 courses of bevacizumab plus modified FOLFOX6. The metastatic lesions disappeared and were judged to be CR. Therefore, she was followed-up with the oral administration of UFT. Metastases of liver and lymph nodes of the mediastinum were detected in May, 2008, for which she received 4 courses of bevacizumab plus FOLFIRI2. Because the effects of the chemotherapy were judged to be CR, she continued with 4 courses of the same regimen. The regimen was discontinued due to diarrhea, and she therefore began to receive 4 courses of bevacizumab plus LV/5-FU regimens. CR has been maintained at present, over 7 years after the initial surgery.
一名35岁女性于2005年2月因升结肠癌伴多发肝转移接受了半结肠切除术和射频消融术。术后她接受了肝动脉灌注5-氟尿嘧啶化疗，并在术后10个月接受优福定全身化疗。2006年3月发现吻合口局部复发，她接受了切除术。随后进行了6个疗程的改良FOLFOX6辅助化疗。2007年3月因发现多发肝转移和淋巴结转移，她再次接受了射频消融术和6个疗程的改良FOLFOX6辅助化疗。肝转移灶消失，但淋巴结转移仍存在。因此，她接受了4个疗程的贝伐单抗联合改良FOLFOX6治疗。转移灶消失，判断为完全缓解（CR）。因此，她接受优福定口服进行随访。2008年5月发现肝脏和纵隔淋巴结转移，为此她接受了4个疗程的贝伐单抗联合FOLFIRI2治疗。由于化疗效果判断为CR，她继续接受4个疗程的相同方案治疗。因腹泻停止该方案，因此她开始接受4个疗程的贝伐单抗联合亚叶酸钙/5-氟尿嘧啶方案治疗。目前仍维持完全缓解状态，距初次手术已超过7年。
